Introduction
============

Colorectal incidentalomas (CIs) are defined as unexpected colorectal findings that are discovered on an imaging study unrelated to the large bowel. CIs represent a challenge for the clinicians: some of these findings are benign but the risk of malignancy in CIs might be significant.[@b1-rado-48-02-99]

As Fluorine-18-Fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography (^18^F-FDG-PET or PET/CT) are increasingly used, especially for oncologic patients, incidental uptake detected by these functional imaging methods are also increasing. ^18^F-FDG-PET or PET/CT may sometimes reveal an unexpected area of increased radiopharmaceutical uptake within the large bowel in patients referred for other diseases and this finding is defined as CI.[@b1-rado-48-02-99],[@b2-rado-48-02-99]

Both focal, segmental and diffuse unexpected ^18^F-FDG uptake in the large bowel were reported. Segmental and diffuse increased uptake of ^18^F-FDG in the large bowel are considered at low risk of malignancy, being more likely associated with inflammation, physiological uptake or radiopharmaceutical excretion. Conversely, unexpected focal ^18^F-FDG uptake in the large bowel is of greater concern since it may represent both benign, pre-malignant (*i.e.* colonic adenomas) or malignant lesions (*i.e.* primary colorectal cancer or metastatic lesions).[@b1-rado-48-02-99],[@b2-rado-48-02-99]

Several articles have reported data about the prevalence and the malignancy risk of focal colorectal incidental uptake (FCIs) detected by ^18^F-FDG-PET or PET/CT with discordant results. A systematic review about this topic and a meta-analysis providing pooled estimates of prevalence and malignancy risk of FCIs detected by ^18^F-FDGPET or PET/CT are still lacking. Therefore, the objective of our article is to meta-analyze published data about prevalence and malignancy risk of FCIs detected by ^18^F-FDG-PET or PET/CT, in order to derive more robust estimates in this regard.

Methods
=======

Search strategy
---------------

A comprehensive computer literature search of the PubMed/MEDLINE and Scopus databases was conducted to find relevant published articles on the prevalence and malignancy risk of FCIs detected by ^18^F-FDG-PET or PET/CT. We used a search algorithm that was based on a combination of the terms: "incidental" AND "PET" OR "positron emission tomography" OR "fluorodeoxyglucose" OR "FDG". No beginning date limit was used; the search was updated until July 31^st^, 2012. Only articles in English language were selected. To expand our search, references of the retrieved articles were also screened for additional studies.

Study selection
---------------

Original articles investigating both the prevalence and the malignancy risk of FCIs detected by ^18^F-FDG-PET or PET/CT were eligible for inclusion. The exclusion criteria were: a) articles not providing information about prevalence or malignancy risk of FCIs detected by ^18^F-FDG-PET or PET/CT; b) articles not in English language; c) overlap in patient data (in this case the most complete article was included). Three researchers independently reviewed the titles and abstracts of the retrieved articles, applying the inclusion and exclusion criteria mentioned above. Articles were rejected if they were clearly ineligible. The same three researchers then independently reviewed the full-text version of the remaining articles to determine their eligibility for inclusion.

Data extraction
---------------

For each included study, information was collected concerning basic study data (authors, year of publication, country), instrumentation used (PET or PET/CT), number of patients evaluated with PET or PET/CT, number of FCIs detected by PET or PET/CT, number of FCIs verified by colonoscopy or histology, final diagnosis of FCIs, average standardized uptake values (SUV) in malignant, premalignant and benign FCIs.

Statistical analysis
--------------------

The prevalence of patients with FCIs who underwent PET or PET/CT was obtained from individual studies using this formula: prevalence of FCIs = number of patients with FCIs / number of patients evaluated with PET or PET/CT ×100.

The risk of malignant or premalignant FCIs detected by PET or PET/CT was obtained from individual studies using this formula: risk of malignant or premalignant FCIs = number of malignant or premalignant lesions found between FCIs / number of FCIs revealed by PET or PET/CT and verified by colonoscopy or histology ×100.

Patients with a history of colorectal cancer were excluded from the analysis.

A random-effects model was used for statistical pooling of the data; pooled data were presented with 95% confidence intervals (95% CI) and displayed using forest plots. A I-square statistic was also performed to test for heterogeneity between studies. A sub-analysis of the risk of malignant and premalignant FCIs taking into account different geographic areas was carried out. Statistical analyses were performed using StatsDirect statistical software version 2.7.9 (StatsDirect Limited, UK).

Results
=======

The comprehensive computer literature search from PubMed/MEDLINE and Scopus databases revealed 519 articles. Reviewing titles and abstracts, 492 articles were excluded because they did not report any data on prevalence neither on malignancy risk of FCIs detected by ^18^F-FDG-PET or PET/CT. One article was excluded because not in English language.[@b3-rado-48-02-99]

Twenty-six articles were selected and retrieved in full-text version; seven additional studies were found screening the references of these articles. Out of these 33 articles potentially eligible for inclusion, after reviewing the full-text article, one article was excluded due to possible data overlap.[@b4-rado-48-02-99] Finally, 32 studies including 89,061 patients met all inclusion and exclusion criteria, and they were included in our meta-analysis ([Figure 1](#f1-rado-48-02-99){ref-type="fig"}) [@b2-rado-48-02-99],[@b5-rado-48-02-99]--[@b35-rado-48-02-99]; 18 studies had data to calculate the pooled prevalence of FCIs and 31 studies had data to calculate the pooled risk of malignant of premalignant FCIs. The characteristics of the included studies are presented in [Table 1](#t1-rado-48-02-99){ref-type="table"}.

Overall, the pooled prevalence of FCIs detected by ^18^F-FDG-PET or PET/CT in the included studies was 3.6% (95% CI: 2.6--4.7%), ranging from 0.4% to 16.3% ([Figure 2](#f2-rado-48-02-99){ref-type="fig"}). Overall, 1,044 FCIs detected by ^18^F-FDG-PET or PET/CT underwent colonoscopy or histology verification. Pooled risk of malignant or premalignant lesions between FCIs was 68% (95% CI: 60--75%), ranging from 16% to 100% in the included studies ([Figure 3](#f3-rado-48-02-99){ref-type="fig"}). The included studies were statistically heterogeneous (I-square: \> 75%) both for prevalence and risk of malignant or pre-malignant FCIs.

Concerning geographic distribution, the pooled risk of malignant or premalignant lesions in FCIs was lower in Asia-Oceania (62%; 95% CI: 43--79%) compared to America (70%; 95% CI: 61--79%) and Europe (70%; 95% CI: 65--74%).

A statistically significant difference in average SUV between malignant, premalignant and benign FCIs was reported in some articles; nevertheless, a significant overlap about SUV was found between these three groups ([Table 1](#t1-rado-48-02-99){ref-type="table"}).

Discussion
==========

The increasing use of ^18^F-FDG-PET and PET/CT is associated with a concomitant increase in the number of patients with FCIs. The major difference between PET/CT and other imaging studies is that PET/CT provides both anatomic and metabolic information about incidental lesions found in the large bowel. The pattern of ^18^F-FDG uptake in the large bowel on PET imaging influences the likelihood of malignancy. Diffuse and segmental increased uptake detected at ^18^F-FDG-PET or PET/CT in the large bowel are usually associated with benign conditions [@b1-rado-48-02-99],[@b2-rado-48-02-99]: such cases were not covered by this meta-analysis. We focused our analysis on FCIs because they can be associated with malignant or premalignant conditions in a significant number of cases.[@b1-rado-48-02-99],[@b2-rado-48-02-99]

Several single-center studies have reported the prevalence of FCIs and risk of malignant and premalignant lesions between FCIs detected by ^18^F-FDG-PET or PET/CT with discordant findings.[@b2-rado-48-02-99],[@b5-rado-48-02-99]--[@b35-rado-48-02-99] In order to derive more robust estimates and obtain evidence-based data about this topic, we performed a meta-analysis pooling published data.

Pooled results of our meta-analysis indicate that FCIs are observed in about 3.6% of patients performing ^18^F-FDG-PET or PET/CT. Moreover, in our pooled analysis FCIs were associated with a high risk of malignant or premalignant lesions (68%), considering colonoscopy or histology confirmation as reference standard. Therefore, whenever a focal hot spot is detected within the large bowel, the ^18^F-FDG-PET or PET/CT report should suggest further investigation, such as colonoscopy, in order to exclude a malignant or premalignant lesions.[@b1-rado-48-02-99],[@b2-rado-48-02-99]

In the calculation of pooled malignancy risk, we considered premalignant lesions together with malignant lesions because colonic adenomas can transform from adenoma to carcinoma and progress insidiously in asymptomatic patients.

Performing a sub-analysis for geographic areas we found that the risk of malignant or premalignant lesions between FCIs was higher in America and Europe compared to Asia and Oceania. A possible explanation of this finding is that the prevalence of colorectal cancer is superior in these geographic areas.[@b36-rado-48-02-99]

A significant difference in average SUV between malignant, premalignant and benign FCIs was reported in some articles ([Table 1](#t1-rado-48-02-99){ref-type="table"}). Nevertheless, a significant overlap about SUV was found between these three groups. Therefore, SUV alone should not be used to differentiate between malignant, premalignant and benign FCIs. Indeed, it is well known that SUV is influenced by several factors, related to the patient as well as to technical aspects and procedures. Any calculation of a pooled SUV obtained by different studies - acquired with different tomographs, scan protocols, ^18^F-FDG injected activity, and patient characteristics - is in our opinion inappropriate, and therefore we decided not to meta-analyze data about SUV.

The present study has some limitations, related to the included articles, such as the selection bias in the calculation of malignancy risk and the heterogeneity between studies. Indeed, only a percentage of FCIs detected by ^18^F-FDG-PET or PET/CT underwent colonoscopy or histopathology confirmation in the included studies and this may represent a selection bias in the calculation of the risk of malignant or premalignant lesions. Furthermore, the included studies were statistically heterogeneous in their estimates of prevalence of FCIs and risk of malignant or premalignant lesions. This heterogeneity is likely to stem from diversity in methodological aspects between different studies. The baseline differences between the patients performing PET or PET/CT in the included studies may have contributed to the observed heterogeneity too. However, such variability was accounted for in a random-effects model.

Lastly, we did not perform a sub-analysis taking into account the device used (PET vs. PET/CT) or the site of FCIs (rectum and different colonic segments) because sufficient data in this regard could not be retrieved from the included studies.

Conclusions
===========

FCIs are observed in a not negligible number of patients who undergo ^18^F-FDG-PET or PET/CT studies with a high risk to be malignant or premalignant lesions. SUV is not reliable as a tool to differentiate between malignant, premalignant and benign FCIs. Further investigation, such as colonoscopy, is warranted whenever FCIs are detected by ^18^F-FDG-PET or PET/CT in order to exclude malignant or premalignant lesions.
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###### 

Characteristics of the included studies about focal colorectal incidental uptake detected by ^18^F-FDG PET or PET/CT

  **Authors**                **Year**   **Country**               **Device used**   **No. of patients evaluated**   **No. of patients with FCIs**   **No. of FCIs**   **No. of FCIs verified by colonoscopy or histology**   **Final diagnosis of FCIs**   **Average SUV in FCIs**                                                                                                                                             
  -------------------------- ---------- ------------------------- ----------------- ------------------------------- ------------------------------- ----------------- ------------------------------------------------------ ----------------------------- ------------------------- ------ ------ ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------
  Zhuang H et al.            2002       USA/Brazil                PET               197                             17                              17                14                                                     5                             1                         8      n.a.   n.a.                                                          n.a.                                                          
  Tatlidil R et al.          2002       USA                       PET               3000                            n.a.                            n.a.              13                                                     6                             4                         3      0      n.a.                                                          n.a.                                                          n.a.
  Chen YK et al.             2003       Taiwan                    PET               3210                            22                              23                23                                                     6                             17                        0      0      5.74 ± 2.26[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}   3.56 ± 0.68[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}   n.a.
  Pandit-Taskar N et al.     2004       USA                       PET               1000                            n.a                             n.a.              10                                                     1                             7                         0      2      13.6                                                          7.0 ± 3.0                                                     n.a.
  Agress H et al.            2004       USA                       PET               1750                            n.a.                            n.a.              27                                                     3                             18                        3      3      n.a                                                           n.a                                                           n.a.
  Kamel EM et al.            2004       Switzerland               PET/CT            3281                            n.a.                            n.a.              54                                                     9                             27                        9      9      n.a                                                           n.a                                                           n.a.
  Lardinois D et al.         2005       Switzerland/Russia        PET/CT            350                             11                              11                11                                                     0                             8                         3      0      n.a.                                                          n.a                                                           n.a.
  Ishimori T et al.          2005       USA                       PET/CT            1912                            8                               8                 4                                                      4                             0                         0      0      n.a.                                                          n.a.                                                          n.a.
  Gutman F et al.            2005       France                    PET/CT            1716                            45                              n.a.              21                                                     3                             10                        1      7      15 ± 11.6                                                     12.0±3.7                                                      25
  van Westreenen HL et al.   2005       The Netherlands           PET               366                             11                              11                8                                                      2                             6                         0      0      n.a.                                                          n.a.                                                          n.a.
  Israel O et al.            2005       Israel                    PET/CT            4390                            n.a.                            n.a.              24                                                     6                             9                         3      6      n.a.                                                          14.0 ± 10.5                                                   n.a.
  Even-Sapir E et al.        2006       Israel                    PET/CT            2360                            33                              39                29                                                     13                            7                         5      4      n.a                                                           n.a                                                           n.a.
  Wang G et al.              2007       China/Australia           PET/CT            1727                            n.a.                            n.a.              11                                                     1                             3                         4      3      n.a.                                                          n.a.                                                          n.a.
  Hemandas AK et al.         2008       UK                        PET/CT            110                             10                              10                7                                                      0                             7                         0      0      n.a.                                                          n.a.                                                          n.a.
  Terauchi T et al.          2008       Japan                     PET               2911                            n.a.                            111               111                                                    7                             11                        9      84     8.31                                                          n.a.                                                          n.a.
  Lee ST et al.              2008       Australia                 PET/CT            2916                            85                              95                45                                                     12                            24                        2      7      n.a.                                                          n.a.                                                          n.a.
  Tessonnier L et al.        2008       France                    PET/CT            4033                            n.a.                            n.a.              44                                                     8                             25                        4      7      12.3 ± 5                                                      9.8 ± 6.1                                                     8.2±2.1
  Strobel K et al.           2009       Switzerland               PET/CT            598                             n.a.                            14                14                                                     5                             8                         0      1      n.a.                                                          n.a.                                                          n.a.
  Lee JC et al.              2009       Australia                 PET/CT            1665                            62                              70                35                                                     11                            12                        5      7      n.a.                                                          n.a.                                                          n.a.
  Weston BR et al.           2010       USA                       PET/CT            330                             50                              52                52                                                     10                            25                        2      15     17.2[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}          14.2 ± 7.2[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}    n.a.
  Kei PL et al.              2010       USA/Singapore/Hong Kong   PET/CT            2250                            n.a.                            n.a.              22                                                     4                             13                        1      4      n.a.                                                          20.7 ± 11.3[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}   12.0[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}
  Özkol V et al.             2010       Turkey                    PET/CT            2370                            n.a                             n.a.              16                                                     3                             3                         7      3      n.a.                                                          n.a.                                                          n.a.
  Luboldt W et al.           2010       Germany                   PET/CT            2338                            50                              n.a.              n.a.                                                   n.a.                          n.a.                      n.a.   n.a.   n.a.                                                          n.a.                                                          n.a.
  Peng J et al.              2011       China                     PET/CT            10978                           148                             n.a.              125                                                    32                            23                        5      65     9.7[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}           8.2[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}           6.1[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}
  Treglia G et al.           2012       Italy                     PET/CT            6000                            64                              n.a.              51                                                     13                            19                        8      11     9.6 ± 4.7                                                     8.5 ± 5.2                                                     6.5 ± 3.6
  Farquharson AL et al.      2012       UK                        PET/CT            555                             53                              n.a.              26                                                     2                             17                        3      4      n.a.                                                          n.a.                                                          n.a.
  Salazar Andia G et al.     2012       Spain                     PET/CT            2220                            n.a.                            n.a.              55                                                     13                            27                        10     5      n.a.                                                          n.a.                                                          n.a.
  Oh J-R et al.              2012       Republic of Korea         PET/CT            21317                           n.a.                            296               102                                                    32                            43                        13     14     13.6 ± 4.9[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}    8.4 ± 4.5[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}     6.8[^\*^](#tfn2-rado-48-02-99){ref-type="table-fn"}
  Lin M et al.               2012       Australia                 PET/CT            649                             n.a.                            n.a.              18                                                     3                             9                         4      2      6.0                                                           10.4                                                          5.8
  Yildirim D et al.          2012       Turkey                    PET/CT            823                             28                              28                19                                                     6                             2                         1      10     n.a                                                           n.a                                                           n.a.
  Gill RS et al.             2012       Canada                    PET or PET/CT     1500                            21                              21                7                                                      2                             2                         1      2      7.4                                                           n.a.                                                          4.1
  Shim JH et al.             2012       South Korea               PET/CT            239                             39                              46                46                                                     8                             24                        14     8.9    5.5                                                           n.a.                                                          

FCIs = focal colorectal incidental uptake; pts = patients; n.a. = not available;

significant statistical difference
